No Data
Immunotech Biopharm's 2024 Loss Narrows
Hong Kong Stock Announcement Gold Mining | CHINA OVERSEAS reported annual performance with a profit attributable to Shareholders of 15.636 billion yuan, a decrease of 38.95% year-on-year.
FOSUN PHARMA (02196) intends to invest 0.27 billion yuan to subscribe for 0.105 billion newly issued shares of UnitedHealth; Chugai Pharmaceutical-B (02171): A summary of the research results of SRK-015 injection has been accepted for an oral presentation at the 2025 ASCO Annual Meeting.
IMMUNOTECH-B (06978.HK) reported a loss of 0.187 billion yuan for the 2024 fiscal year, a year-on-year decrease of 44.18%.
Glory Financial reported on March 31 that IMMUNOTECH-B (06978.HK) announced its annual performance. For the fiscal year ending December 31, 2024, the group's other income amounted to RMB 33.788 million, representing a year-on-year growth of 220.36%; the annual loss attributable to shareholders was RMB 0.187 billion, narrowing by 44.18% year-on-year; basic loss per share was RMB 0.36. The group's R&D expenses decreased from approximately RMB 0.177 billion for the fiscal year ending December 31, 2023, by about 13.0% to approximately RMB 0.154 billion for the fiscal year ending December 31, 2024, mainly.
Express News | Immunotech Biopharm FY Pretax Profit RMB -186.4 Million
IMMUNOTECH-B: ANNOUNCEMENT OF ANNUAL RESULTSFOR THE YEAR ENDED 31 DECEMBER 2024
IMMUNOTECH-B (06978.HK): The conditional new drug application for EAL has been accepted by the National Medical Products Administration.
On March 31, Gelonghui reported that IMMUNOTECH-B (06978.HK) announced that the conditional new drug application (NDA) for its core candidate product EAL has been accepted by the Drug Evaluation Center (CDE) of the National Medical Products Administration (NMPA) of China. EAL is a broad-spectrum cell immunotherapy product with more than ten years of clinical application in cancer treatment. EAL is a formulation originally derived from T cells activated and expanded using patented methods from the patient's peripheral blood. The product mainly consists of CD8+ cytotoxic T cells (marked by CD3 molecules) as the active ingredient.
